Small Cell Lung Cancer

The overdiagonsis identified in the current study also led to overtreatment in this population, authors found.

A meta-analysis on first-line treatment for non–small cell lung cancer (NSCLC) in clinical trials revealed that inclusion of dexamethasone along side chemotherapy and PD-L1 inhibitors yielded benefits in this patient population.

New research out today details the lack of price reductions seen among recently launched brand-name drugs for non–small cell lung cancer (NSCLC).

Researchers examined differences in lung cancer screening and follow-up rates among individuals residing in Hawaii.

A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.

Investigators identified potential markers of chemotherapy efficacy in patients with non–small cell lung cancer.

A new analysis published in JAMA Oncology found the United States Preventive Services Task Force's (USPSTF) 2021 update to lung cancer screening recommendations helped close a racial disparity gap in screening rates.

A recent analysis provides updated data on non–small cell lung cancer in the United States.

An analysis concluded that cemiplimab may be more cost-effective than chemotherapy as first-line treatment for some US patients with non–small cell lung cancer (NSCLC).

Cullinan Oncology’s CLN-081 today received a Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).

This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.

On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.

Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.

The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.

A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.

Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.

Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.

Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.

The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.

There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.

NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.

Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.

Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.

Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.

Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.